Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 2/20 | 0.47 |
| ▸ | NOS3 | P29474 | 1/20 | 0.47 |
| ▸ | PRKCI | P41743 | 3/20 | 0.40 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.38 |
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.37 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.35 |
| ▸ | ATR | Q13535 | 1/20 | 0.35 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.34 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.33 |
| ▸ | USP7 | Q93009 | 1/20 | 0.33 |
| ▸ | VCP | P55072 | 1/20 | 0.33 |
| ▸ | PTPRC | P08575 | 1/20 | 0.33 |
| ▸ | PTPRA | P18433 | 1/20 | 0.33 |
| ▸ | PTPRB | P23467 | 1/20 | 0.33 |
| ▸ | PTPRE | P23469 | 1/20 | 0.33 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26331239 | 0.75 | NOS2 (0.58) | NOS2NOS3PRKCIUSP7 | |
| SCHEMBL6931488 | 0.72 | NOS2 (0.55) | NOS2NOS3PRKCINAPRT | |
| SCHEMBL14141522 | 0.70 | NOS2 (0.51) | NOS2NOS3PRKCINAPRTUSP7 | |
| SCHEMBL4673785 | 0.69 | NOS2 (0.55) | NOS2NOS3PRKCINAPRTUSP7 | |
| SCHEMBL357771 | 0.69 | NOS2 (0.64) | NOS2NOS3PRKCIUSP7 | |
| SCHEMBL3264474 | 0.67 | NOS2 (0.67) | NOS2NOS3PRKCIUSP7 | |
| SCHEMBL31430338 | 0.66 | TKT (0.39) | SHMT2GPR35PIK3C3 | |
| SCHEMBL11743612 | 0.65 | NOS2 (1.00) | NOS2NOS3PRKCIUSP7 | |
| SCHEMBL30664052 | 0.65 | NOS2 (1.00) | NOS2NOS3PRKCIUSP7 | |
| SCHEMBL21551505 | 0.65 | MAPT (0.60) | GPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | NOS2 760/4885NOS3 556/4885PRKCI 3707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.